Business
WELL Health Reports Record Revenue, Record Adjusted EBITDA, and Record Adjusted Net Income in Q3-2025 Driven by Strong Performance in Core Canadian Businesses
WELL achieved record quarterly revenues of $364.6 million in Q3-2025, an increase of 56% compared...
About this update from Well Health Technologies Corp.
[{"type":"text","content":"WELL Health Reports Record Revenue, Record Adjusted EBITDA, and Record Adjusted Net Income in Q3-2025 Driven by Strong Performance in Core Canadian Businesses\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n.bwalignr { text-align: right; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwlistdecimal { list-style-type: decimal }\n.bwlistdisc { list-style-type: disc }\n.bwpadb3 { padding-bottom: 4px }\n.bwpadl0 { padding-left: 0px }\n.bwpadl1 { padding-left: 5px }\n.bwpadl4 { padding-left: 20px }\n.bwpadr0 { padding-right: 0px }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwvertalignb { vertical-align: bottom }\n.bwvertalignt { vertical-align: top }\n.bwwidth1 { width: 1% }\n.bwwidth100 { width: 100% }\n.bwwidth11 { width: 11% }\n.bwwidth2 { width: 2% }\n.bwwidth42 { width: 42% }\n \n\n\n\n\n WELL achieved record quarterly revenues of $364.6 million in Q3-2025, an increase of 56% compared to Q3-2024 driven by organic growth and acquisitions. Excluding the impact of Circle Medical’s deferred revenue adjustments or “CM Deferrals”\n \n (1)\n \n , revenue would have been $347.0 million in Q3-2025, representing 48% YoY growth.\n \n\n WELL achieved record Adjusted EBITDA\n \n (1)\n \n of $59.9 million in Q3-2025, an increase of 296% compared to $15.1 million in Q3-2024, representing Adjusted EBITDA\n \n (1)\n \n margin of 16.4%. Excluding the impact from CM Deferrals, Adjusted EBITDA\n \n (1)\n \n would have been $42.3 million in Q3-2025, representing 180% YoY growth.\n \n\n Canadian Patient Services revenue and Adjusted EBITDA\n \n (1)\n \n was $110.1 million and $14.1 million respectively in Q3-2025, an increase of 41% and 47%, driven by acquisitions and organic growth of 16% for the Canadian Patient Services business.\n \n\n WELL’s majority owned subsidiary, WELLSTAR Technologies Corp. announced a financing for $62 million at a 50% increase in share price relative to its prior December 2024 financing, reflecting approximately $535 million post-money fully-diluted transaction valuation for WELLSTAR, with some of Canada’s most prominent fund investors providing the company with sufficient capital to continue to invest in organic growth ...